Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1333-1342

  Lama, Gina ^a   Mangiola, Annunziato ^a   Anile, Carmelo ^a   Sabatino, Giovanni ^a   De Bonis, Pasquale ^a   Lauriola, Libero ^a   Giannitelli, Cecilia ^a   Torre, Giuseppe L A ^a   Jhanwar Uniyal, Meena ^b   Sica, Gigliola ^a   Maira, Giulio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

ERK1 2; Glioblastoma; Peritumor tissue

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGED; BRAIN NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 34447251515     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1333     Document Type: Article

References (44)

1. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H and Cavenee WK: Glioblastoma. In: Pathology and Genetics of Tumours of the Nervous System. Kleihues P and Cavenee WK (eds). IARC Press, Lyon, pp29-39, 2000.
2. Stupp R, Masori WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet 361: 323-331, 2003.
4. McLendon RE and Halperin EC: Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 98: 1745-1748, 2003.
5. Burger PC, Heinz ER, Shibata T and Kleihues P: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68: 698-704, 1988.
6. Kelly PJ: Technology in the resection of gliomas and the definition of madness. J Neurosurg 101: 284-286, 2004.
7. Silbergeld DL and Chicoine MR: Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86: 525-531, 1997.
8. Hochberg FH and Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907-911, 1980.
9. Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001.
10. Boudreau CR, Yang I and Liau LM: Gliomas: advances in molecular analysis and characterization. Surg Neurol 64: 286-294, 2005.
11. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B and Nister M: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219, 1992.
12. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF and Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172, 1991.
13. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS and Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965-2969, 1992.
14. Quan AL, Barnett GH, Lee SY, et al: Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 63: 695-703, 2005.
15. Chakravarti A, Seiferheld W, Tu X, et al: Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62: 318-327, 2005.
16. Shinojima N, Tada K, Shiraishi S, et al: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962-6970, 2003.
17. Goldman CK, Kim J, Wong WL, King V, Brock T and Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-133, 1993. (Pubitemid 23071308)
18. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and De Pinho RA: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001.
19. Weindel K, Moringlane JR, Marmé D and Weich HA: Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery 35: 439-449, 1994.
20. Marshall CJ: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 1995.
21. Klemke RL, Cai S, Giannini AL, Gallagher PJ, De Lanerolle P and Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137: 481-492, 1997.
22. Mandell JW and VandenBerg SR: ERK/MAP kinase is chronically activated in human reactive astrocytes. Neuroreport 10: 3567-3572, 1999.
23. Sweatt JD: The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76: 1-10, 2001.
24. Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA and Pandey GN: Reduced activation and expression of ERK1/2 MAP kinase in the post mortem brain of depressed suicide subjects. J Neurochem 77: 916-928, 2001.
25. Gioia M, Galbiati S, Rigamonti L, Moscheni C and Gagliano N: Extracellular signal-regulated kinases 1 and 2 phophorylated neurons in the tele- and diencephalon of rat after visceral pain stimulation: an immunocytochemical study. Neurosci Lett 308: 177-180, 2001. (Pubitemid 32710152)
26. Mandell JW, Hussaini IM, Zecevic M, Weber MJ and Vanden Berg SR: In situ visualization of intratumor growth factor signaling. Immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 153: 1411-1423, 1998.
27. Mangiola A, Maira G, De Bonis P, Porso M, Pettorini B, Sabatino G and Anile C: Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neurooncol 76: 159-163, 2006.
28. Hoelzinger DB, Mariani L, Weis J, et al: Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7: 7-16, 2005.
29. Kapoor GS and O'Rourke DM: Mitogenic signaling cascades in glial tumors. Neurosurgery 52: 1425-1435, 2003.
30. Tournier C, Pomerance M, Gavaret JM and Pierre M: MAP kinase cascade in astrocytes. Glia 10: 81-88, 1994.
31. Roback JD, Marsh HN, Downen M, Palfrey HC and Wainer BH: BDNF-activated signal transduction in rat cortical glial cells. Eur J Neurosci 7: 849-862, 1995.
32. Leirdal M and Sioud M: Protein kinase C alpha isoform regulates the activation of the MAP kinase ERK1/2 in human glioma cells: involvement in cell survival and gene expression. Mol Cell Biol Res Commun 4: 106-110, 2000. (Pubitemid 32183171)
33. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S and Pouysségur J: Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 18: 664-674, 1999.
34. Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852, 1994.
35. Mansour SJ, Matten WT, Hermann AS, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994. (Pubitemid 24281496)
36. Weber JD, Raben DM, Phillips PJ and Baldassare JJ: Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 326: 61-68, 1997.
37. Fiano V, Ghimenti C, Imarisio S, Silengo L and Schiffer D: pAkt, cyclin D1 and p27/Kip.1 in glioblastomas with and without EGFR amplification and PTEN mutation. Anticancer Res 24: 2643-2647, 2004.
38. Krueger JS, Keshamouni VG, Atanaskova N and Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20: 4209-4218, 2001.
39. Tanimura S, Nomura K, Ozaki K, Tsujimoto M, Kondo T and Kohno M: Prolonged nuclear retention of activated extracellular signal-regulated kinases 1/2 is required for hepatocyte growth factor-induced cell motility. J Biol Chem 277: 28256-28264, 2002. (Pubitemid 34966780)
40. Lakka SS, Jasti SL, Kyritsis AP, Yung WKA, Ali-Osman F, Nicolson GL and Rao JS: Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades. Clin Exp Metastasis 18: 245-252, 2000.
41. Angers-Loustau A, Hering R, Werbowetski TE, Kaplan DR and Del Maestro RF: SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res 2: 595-605, 2004.
42. Mawrin C, Diete S, Treuheit T, et al: Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol 23: 641-648, 2003.
43. Pelloski CE, Lin E, Zhang Li, et al: Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12: 3935-3941, 2006.
44. Mischel PS and Cloughesy TF: Targeted molecular therapy of GBM. Brain Pathol 13: 52-61, 2003.